Prestige Biopharma Confirms Final Equivalence of Herceptin Biosimilar
[Asia Economy Reporter Ji Yeon-jin] Prestige BioPharma announced on the 24th that it has finally confirmed the equivalence in efficacy, safety, and pharmacokinetics between its Herceptin biosimilar (HD201, Tuznue, Tuznue®) and the original drug Herceptin in the Phase 3 clinical trial results.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- [Breaking] President Lee: "Korea and Japan Agree on the Need for Rapid Restoration of Peace and Stability in the Middle East"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "With the equivalence proven, we expect to provide more economical treatment opportunities to patients suffering from breast cancer through market entry in Europe and worldwide after product approval."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
